Davesomeran API Manufacturers

General Description:

Davesomeran, identified by CAS number 2798905-80-1, is a notable compound with significant therapeutic applications. Davesomeran is a mRNA vaccine used in conjunction with as part of the Moderna Bivalent COVID-19 vaccine. Similar to the previous Moderna COVID-19 vaccine, Moderna Bivalent vaccine encodes the full-length pre-fusion stabilized spike (S) protein to elicit an immune response. However, with the addition of davesomeran, Moderna Bivalent vaccine offers protection against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants. A phase 2 and 3 open-label study in participants 18 years or older who had previously received a two-dose primary series and one booster dose of Moderna COVID-19 Vaccine demonstrated that the Moderna Bivalent vaccine elicit a higher seroresponse both against the original SARS-CoV-2 strain and the BA.4/5 strain compared to that of the Moderna COVID-19 Vaccine. In October 22nd 2022, the FDA approved the Moderna Bivalent Vaccine as a booster in patients 6 years or older, administered at least 2 months after completion of primary vaccination or receipt of the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine. On November 3rd 2022, Health Canada also approved the Moderna Bivalent Vaccine as a booster shot in individuals 18 years of age or older.

Indications:

This drug is primarily indicated for: Moderna COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) is a mixture of 2 mRNA vaccines, and , and is indicated for active immunization against COVID-19. It may be used in patients between 6 months and 5 years of age as a single booster dose at least 2 months following completion of a primary vaccination series with the monovalent Moderna COVID-19 vaccine. It is also indicated for use in patients ≥6 years of age as a single booster dose following completion of either primary vaccination with any authorized COVID-19 vaccine, or following receipt of the most recent booster dose with any authorized monovalent COVID-19 vaccine. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Davesomeran undergoes metabolic processing primarily in: There is limited pharmacokinetic information. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Davesomeran are crucial for its therapeutic efficacy: There is limited pharmacokinetic information. The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Davesomeran is an important consideration for its dosing schedule: There is limited pharmacokinetic information. This determines the duration of action and helps in formulating effective dosing regimens.

Protein Binding:

Davesomeran exhibits a strong affinity for binding with plasma proteins: There is limited pharmacokinetic information. This property plays a key role in the drug's pharmacokinetics and distribution within the body.

Route of Elimination:

The elimination of Davesomeran from the body primarily occurs through: There is limited pharmacokinetic information. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Davesomeran is distributed throughout the body with a volume of distribution of: There is limited pharmacokinetic information. This metric indicates how extensively the drug permeates into body tissues.

Clearance:

The clearance rate of Davesomeran is a critical factor in determining its safe and effective dosage: There is limited pharmacokinetic information. It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Davesomeran exerts its therapeutic effects through: Similar to the previous Moderna COVID-19 Vaccine, the Moderna Bivalent vaccine targets the S spike protein on the membrane of the SARS-CoV-2 virus, with the added immunogenicity against the Omicron variants from . In patients 18 years old or older, Moderna Bivalent vaccine resulted in a 74.9% seroresponse rate compared to 53.1 % seroresponse rate for . The seroresponse rate was also higher against the original SARS-CoV-2 strain for Moderna bivalent vaccine compared to that of . The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Davesomeran functions by: The Moderna Bivalent vaccine contains 2 ingredients: davesomeran and . They both contains synthetic nucleoside-modified messenger RNA (mRNA) encapsulated in Lipid nanoparticle (LNP) encoding the full-length, pre-fusion stabilized spike protein (S) of SARS-CoV-2, although davesomeran's mRNA specifically targets the BA.4/5 Omicron variants with the L452R and F486V mutations in the S protein. The S protein is a major membrane glycoprotein that can bind to the ACE2 receptor in targeted host cells. Due to its location, the S protein is the main target for most mRNA vaccines due to its immunogenicity. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Categories:

Davesomeran is categorized under the following therapeutic classes: COVID-19 Vaccines, Vaccines, Viral Vaccines. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.